BREAKING NEWS – US FDA Approves Lutetium Lu 177 dotatate (Lutathera®) – PRRT?

PRRT was approved in USA on 26 Jan 2018. The approval is for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. CLICK HERE.

The extended access program (trial) is no longer offered but these locations should be ahead of the game in terms of provision, notwithstanding insurance and provision of sufficient nuclear material.

Read more about PRRT by clicking here

 

Thanks for reading

Ronny

I’m also active on Facebook. Like my page for even more news. I’m also building up this site here: Ronny Allan

Disclaimer

My Diagnosis and Treatment History

Most Popular Posts

Sign up for my twitter newsletter

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!



patients included

Please Share this post

4 thoughts on “BREAKING NEWS – US FDA Approves Lutetium Lu 177 dotatate (Lutathera®) – PRRT?

Leave a Reply

%d bloggers like this: